Evidence map›Paper›PMID 40799789›Full record

Trial reportOpen forum infectious diseases2025

The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by

Federico Frondizi, Gabriele Maria Leanza, Marta Chiuchiarelli, Francesca Catania, Flavio Sangiorgi, Francesca Giovannenze, Eleonora Taddei, Enrica Tamburrini, Carlo Torti, Giancarlo Scoppettuolo

Abstract readClinical Trial
In one paragraph

Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Federico FrondiziSezione Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Roma, Italia.
Gabriele Maria LeanzaSezione Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Roma, Italia.ORCID https://orcid.org/0000-0001-6547-4395
Marta ChiuchiarelliFondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia- Dipartimento di Scienze Mediche e Chirurgiche- UOC Malattie infettive, Rome, Italy.ORCID https://orcid.org/0009-0006-1591-5723
Francesca CataniaSezione Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Roma, Italia.
Flavio SangiorgiSezione Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Roma, Italia.
Francesca GiovannenzeFondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia- Dipartimento di Scienze Mediche e Chirurgiche- UOC Malattie infettive, Rome, Italy.
Eleonora TaddeiFondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia- Dipartimento di Scienze Mediche e Chirurgiche- UOC Malattie infettive, Rome, Italy.
Enrica TamburriniSezione Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Roma, Italia.
Carlo TortiSezione Malattie Infettive, Dipartimento di Sicurezza e Bioetica, Università Cattolica S. Cuore, Roma, Italia.
Giancarlo ScoppettuoloFondazione Policlinico Universitario A. Gemelli IRCCS, Roma Italia- Dipartimento di Scienze Mediche e Chirurgiche- UOC Malattie infettive, Rome, Italy.ORCID https://orcid.org/0000-0003-0893-7044

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oritavancin is emerging as a potential alternative to standard antibiotic regimens in the treatment of infective endocarditis caused by gram-positive bacteria, though evidence remains limited. We hereby report 7 cases of enterococcal endocarditis treated with oritavancin as consolidation therapy, resulting in 6 cures and 1 relapse.

Indexed as

endocarditisEnterococcusoritavancin

Identifiers

PMID40799789
PMCPMC12342531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.